ASH News Daily 2017 - Issue 1 - B-23

ASH News Daily

Saturday, December 9, 2017

Page B-23
®

Sunday's Course Directors' Workshop
to Spotlight Foundational Learning Principles

SH's popular Course Director's Workshop gives attendees practical tips and a place
of camaraderie for those involved
with teaching hematology to medical students. This year's program
will present the topic, "Pedagogy,
New Techniques, Scholarship, and
ASH MEI Spotlight." Dr. Leslie Ellis
returns to lead the workshop, and
four presenters will contribute their
breadth of knowledge on a range
of foundational principles, including include Knowles' adult learning

Need a new professional
headshot or want your current one replaced? Stop by
Headshot Alley in the Exhibit Hall during exhibit hours
Saturday through Monday
to take a headshot that will
be sent to you via email for
immediate
downloading.
Better yet, your new headshot is FREE!

Research Methodology: Amy K.
O'Sullivan, PhD, Innovus Pharma,
Medford, MA
The workshop will also include
a presentation from Dr. Ariela Marshall spotlighting the ASH Medical
Educator's Institute.
The session includes a breakfast
and will be held tomorrow, from 7:00
to 9:00 a.m. All hematology course
directors are welcome to attend. The
meeting will take place at the Omni
Hotel at CNN Center, Grand Ballroom A, North Tower, M4.

theory, the flipped classroom, and
qualitative research methodology:
Knowles' Adult Learning Theory: Jennifer C. Kesselheim, MD,
Med, Dana-Farber Cancer Institute,
Boston, MA
The Flipped Classroom: Pros:
Rajiv K. Pruthi, MBBS, Mayo Clinic,
Rochester, MN
The Flipped Classroom: Cons:
Neil Lachant, MD, MD Anderson
Cancer Center at Cooper, Camden,
NJ
An Overview of Qualitative

Visit Booth #2233
and
Product Theater #4
Sunday, Dec 10, 11:30 AM - 12:30

Headshot Alley

Including pediatric patients with relapsed
or refractory CD33-positive AML

Find out more at

Access and support

MylotargHCP.com

1-877-744-5675

Adverse Cytogenetics: In a subgroup analysis in ALFA-0701, the addition of MYLOTARG to
standard combination chemotherapy did not improve event-free survival in the subgroup
of patients having adverse-risk cytogenetics. For patients being treated with MYLOTARG
in combination with daunorubicin and cytarabine for newly diagnosed de novo AML, when
cytogenetics testing results become available consider whether the potential benefit of
continuing treatment with MYLOTARG outweighs the risks for the individual patient.
Embryo-Fetal Toxicity: MYLOTARG can cause embryo-fetal harm when administered to a
pregnant woman. Advise patients of reproductive potential to use effective contraception during
and for 3 and 6 months following treatment for males and females, respectively. Apprise pregnant
women of the potential risk to the fetus. Advise women to contact their healthcare provider if they
become pregnant or if pregnancy is suspected during treatment with MYLOTARG.
Adverse Reactions: The most common adverse reactions (greater than 15%) were hemorrhage,
infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash,
and mucositis.
Contraindications: Hypersensitivity to MYLOTARG or any of its components. Reactions have
included anaphylaxis.
Please see brief summary of Full Prescribing Information, including BOXED WARNING,
on the following page.
Reference: 1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.
PP-MYL-USA-0115

F:7.625"

Printed in USA/November 2017

T:10"

QT Interval Prolongation: QT interval prolongation has been observed in patients treated
with other drugs containing calicheamicin. When administering MYLOTARG to patients who
have a history of or predisposition for QTc prolongation, who are taking medicinal products
that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain
electrocardiograms and electrolytes prior to the start of treatment and as needed during
administration.

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1